Catalyst Health Ventures


Catalyst Health Ventures (CHV) is a Boston-based venture capital fund that invests in transformative medical technologies addressing global unmet healthcare needs. CHV focuses on therapeutic medical devices, diagnostics, drug delivery and digital health, typically acting as the first institutional investor and supporting companies from seed through Series B and beyond. The firm emphasizes active partnership with founders, providing guidance, network access and support through clinical and regulatory development.

Catalyst Health Ventures

Boston, Massachusetts, United States, North America


Services

Early-stage equity investment

Provides seed through Series B equity financing and can serve as the first institutional investor in a company.

Strategic and operational guidance

Works actively with founders to provide guidance on business strategy, clinical development and regulatory pathways.

Network access and syndicate building

Introduces portfolio companies to co-investors, strategic partners and clinical advisors and helps build complementary syndicates when appropriate.

Regulatory and clinical development support

Supports companies through early clinical development and regulatory processes, including preparing for feasibility and pivotal trials.


Portfolio

Developer of an implantable pulmonary hypertension (PH) system. CHV led or participated in funding rounds (Series A $7.8M; later Series B $31M participation). Aria CV received FDA Breakthrough Device Designation for its PH system and reported first patient implant of the Gen 2 system as part of an ASPIRE PH early feasibility trial (implant completed Feb 14, 2024).

#Medical devices (pulmonary hypertension treatment)

Developing extracardiac temporary and permanent pacing therapies that avoid placing hardware inside the heart. Completed a $25M Series B financing with CHV as an investor; CHV partner Darshana Zaveri to join the board.

#Cardiac pacing / medical devices

Developer of the AngioVac system for extracorporeal removal of thrombus. Vortex Medical was the subject of an acquisition agreement with AngioDynamics (transaction reported in news coverage).

#Endovascular devices / thrombus removal

Listed on CHV's portfolio; specific product or financing details are presented on the company portfolio page.

#Medical devices

Listed on CHV's portfolio.

#Biotechnology / diagnostics

CHV-listed portfolio company; Maxwell Health was acquired by Sun Life Financial (reported in CHV news item).

#Digital health / benefits administration software

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.